PatientSpotlight, by PanaceaIntelPatientSpotlight
SignalApr 29, 20261 min read

Adult RSV vaccination's slow-build season

Adult RSV vaccination programs are entering their second and third seasons - real-world uptake is the test.

Adult RSV vaccination launched with strong trial data. The interesting story is no longer trial efficacy - it is whether routine pharmacy and primary-care delivery actually reaches the at-risk population, and whether year-on-year boosting holds up.

Continue reading

Full intelligence on PanaceaIntel

PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.

New to PanaceaIntel? Request access and the team will reply within one working day.

Related

← Back to Signals
PanaceaIntelPublished by PatientSpotlight, by PanaceaIntel.